23 studies found for:    Open Studies | "Hemorrhagic Fever, Ebola"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Hemorrhagic Fever, Ebola" (23 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: rVSVΔG-ZEBOV
2 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo
3 Recruiting Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Condition: Ebola Virus
Interventions: Biological: VSVG-ZEBOV;   Biological: ChAd3-EBO Z;   Drug: Placebo
4 Not yet recruiting Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
5 Recruiting Efficacy of Favipiravir Against Ebola (JIKI)
Condition: Ebola Virus Disease
Intervention: Drug: Favipiravir
6 Recruiting A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
Condition: Acute Ebola Virus Disease
Intervention: Biological: INTERCEPT Plasma
7 Not yet recruiting Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)
Condition: Ebola Virus Disease
Interventions: Drug: Best Supportive Care;   Drug: Best Supportive Care + Amiodarone
8 Not yet recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
9 Recruiting Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
Conditions: Ebola Virus Disease;   Hemorrhagic Fever
Interventions: Biological: VRC-EBOADC069-00-vp;   Biological: MVA-EbolaZ;   Other: Placebo
10 Not yet recruiting A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV
Condition: Ebola Virus Disease
Interventions: Biological: ChAd3-EBO-Z;   Biological: Ad26.ZEBOV
11 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
12 Not yet recruiting Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults
Condition: Prevention of Ebola Infection
Interventions: Biological: V920 Consistency Lot A;   Biological: V920 Consistency Lot B;   Biological: V920 Consistency Lot C;   Biological: V920 High-dose Lot;   Biological: Placebo to V920
13 Recruiting A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Condition: Ebola Virus Disease
Interventions: Biological: 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV);   Biological: placebo
14 Recruiting A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
Condition: Ebola Virus Disease
Interventions: Biological: MVA-EBO Z;   Biological: ChAd3-EBO Z
15 Recruiting A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Conditions: Filovirus Infections;   Ebola Virus Infection
Interventions: Drug: BCX4430;   Drug: Placebo
16 Recruiting Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Condition: Ebola Vaccine
Interventions: Biological: INO-4201;   Biological: INO-4202;   Biological: INO-4212;   Biological: INO-4212 + INO-9012
17 Recruiting A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults
Condition: Healthy
Interventions: Biological: MVA-BN-Filo;   Biological: Ad26.ZEBOV;   Biological: Placebo
18 Not yet recruiting Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2
Condition: Healthy
Interventions: Biological: Ad26.ZEBOV (5*10^10 viral particles);   Biological: MVA-BN-Filo (1*10^8 infectious units)
19 Recruiting VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults
Condition: Healthy Adult Immune Responses to Vaccine
Interventions: Biological: VRC-EBOMVA079-00-VP (MVA-EbolaZ);   Biological: VRC-EBOADC069-00-VP (cAd3-EBO)
20 Not yet recruiting A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
Condition: Virus Diseases
Interventions: Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years